Paul Auer

Professor

Medical College of Wisconsin
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Patterns of co-occurring early life trauma (ELT), unlike cumulative trauma, are understudied as potential stress-related health risks. DNA methylation (DNAm) is a posited mechanism linking socioenvironmental stress and disease pathogenesis. We assess whether ELT patterns differentially affect adult DNAm, both epigenome-wide and specifically stress-related genes (eg, glucocorticoid receptor gene, NR3C1). Data represent a case-cohort of non-Hispanic white participants (N = 2566) from the Sister Study, a cohort of US women (ages: 35-74; enrollment: 2003-2009; N = 50 884). Early life trauma measures included a count score and 4 latent ELT classes: low ELT (referent); sexual and emotional; high betrayal; and high ELT. We evaluated epigenome-wide DNAm, differentially methylated regions (DMRs), pathway enrichment, and NR3C1-specific methylation from whole blood. Twenty-two differentially methylated Cytosine–phosphate–Guanine (CpG) sites were associated with ELT classes and none with ELT score. Furthermore, 108 DMRs were associated with ELT score (n = 5) and ELT classes: sexual and emotional (n = 7), high betrayal (n = 37), and high ELT (n = 61). Cardiovascular signaling and leptin signaling pathways were both associated with high betrayal and high ELT classes. In NR3C1-specific analyses, 11 CpGs were associated with ELT score (n = 3) and specific ELT classes (n = 9). Results suggest that specific patterns of co-occurring trauma may contribute to meaningful variability in peripheral blood DNAm in adulthood.

Year:

2026

PURPOSE Hematopoietic cell transplantation (HCT) is considered the only curative treatment for patients with myelodysplastic syndrome (MDS), with disease relapse (REL) as the major cause of post-HCT failure. We aimed to conduct a comprehensive genomic screening of prognostic biomarkers associated with post-HCT disease relapse. METHODS In this retrospective, cohort study, we analyzed whole-genome sequencing data from 494 non-Hispanic White patients with MDS who received HCT in the Center for International Blood and Marrow Transplant Research network. Genomic prognostic biomarkers were determined by cause-specific Cox regression multivariable models, with additional sensitivity analyses on unrelated transplant subcohorts and different competing outcomes. Their clinical significance on post-HCT risk stratifications was further evaluated via random survival forest models with optimism-bias adjusted bootstrap procedure. RESULTS Ten novel genomic biomarkers associated with relapse were identified, including somatic mutations in two genes ( HNRNPA3 and TENM2 ), one locus ( HSPC324 ) with a burden of rare germline single-nucleotide variants (SNVs), six loci harboring common SNVs, and one region harboring a structural variant (SV). For prognostic performance comparisons, the combined model that included these novel genomic biomarkers showed significant improvement of concordance indices (0.747 [95% CI, 0.705 to 0.786]) for predicting post-HCT disease relapse, compared with 0.547 (95% CI, 0.503 to 0.595) in the baseline model (Revised International Prognostic Scoring System [IPSS-R] + hypomethylating agents + graft-versus-host disease prophylaxis). Especially, the combined model showed superior risk stratifications for low or intermediate IPSS-R MDS patients with divergent post-HCT outcomes. CONCLUSION Our results suggest that SNVs and SVs beyond recurrent somatic mutations and cytogenetic abnormalities may play important roles in determining post-HCT relapse risk stratification in patients with MDS.

Year:

2026

A wealth of research focused on African American populations has connected rs2814778-CC (“Duffy-null”) to decreased neutrophil (neutropenia) and leukocyte counts (leukopenia). Although it has been proposed that this variant is benign, prior studies have shown that the misinterpretation of Duffy-null–associated neutropenia and leukopenia can lead to unnecessary bone marrow biopsies, inequities in cytotoxic and chemotherapeutic treatment courses, underenrollment in clinical trials, and other disparities. To investigate the phenotypic correlates of Duffy-null status, we conducted a phenome-wide association study across >1400 clinical conditions in All of Us, the Vanderbilt University Medical Center’s Biobank, and the Million Veteran Program. This reveals that Duffy-null status is only reproducibly associated with changes in white blood cell count and not with any disease outcomes. Moreover, we find that Duffy-null–associated neutropenia is on average less severe than other neutropenia cases in All of Us. We also show that this genotype is present in considerable frequencies in All of Us populations that are genetically similar to African (68%) and Middle Eastern (14%) 1000 Genomes/Human Genome Diversity Project reference populations as well as those who identify with >1 race (12%), as Pacific Islander (7%), and as Hispanic (5%). Furthermore, we find that race is not an accurate predictor of Duffy-null status or associated benign neutropenia. Our research suggests that broad genetic screening of rs2814778 across all populations could provide a more robust and accurate understanding of white blood cell count and mitigate resulting health disparities.

Year:

2025

PURPOSE Cancer-related cognitive impairment (CRCI) and cancer-related fatigue (CRF) are reported by approximately 75% of patients receiving chemotherapy for breast cancer and both have been linked to inflammation. We sought to test whether an inflammation polygenic risk score (iPRS) might be associated with CRCI and/or CRF. METHODS Using data from the UK Biobank, we developed an iPRS for the INFLA-Score, a composite measure of C-reactive protein, white cell count, platelet count, and neutrophil-lymphocyte ratio. The iPRS was evaluated for association with CRCI and CRF among women with nonmetastatic breast cancer enrolled in two completed multisite clinical trials: URCC08106 and URCC10055. CRCI and CRF were measured before and after standard-of-care chemotherapy using the FACT-Cog and Multidimensional Fatigue Symptom Inventory–Short Form (MFSI-SF), respectively. Linear regression evaluated the change in FACT-Cog and MFSI scores; logistic regression evaluated binary outcomes of any versus no worsening of scores. Analyses were adjusted for patient and treatment factors. We also performed exploratory genome-wide analyses. RESULTS The cohort included 802 women who received chemotherapy (anthracycline-based = 51.8%; previous surgery = 85.0%) at a median age of 55 years (range = 22-81). The iPRS was associated with a significant decrease in MFSI-SF score (β = –3.29 [95% CI, –6.25 to –0.34]; P = .029) and lower odds of decreased MFSI-SF score (odds ratio, 0.66 [95% CI, 0.47 to 0.93]; P = .016) following chemotherapy. This negative relationship was partially explained by a positive correlation of the iPRS with prechemotherapy MFSI-SF score (β = 4.33 [95% CI, 0.23 to 8.43]; P = .038). The iPRS was not associated with a change in FACT-Cog score (β = –1.12; P = .627), but single nucleotide polymorphism rs9365961 was (β = –10.05; P = 1.46 × 10 −8 ). CONCLUSION If validated, the iPRS could identify patients in need of supportive care interventions to reduce CRF.

Year:

2025

Frequencies of all reported germline CHEK2 variant carriers and carriers of variants concordantly categorized by functional our kinase assays in breast cancer patients and controls in 12 analyzed population datasets.

Year:

2025

Mosaic loss of Y chromosome (mLOY) in blood cells is an age-related somatic mutation, but its relationship with pulmonary health remains undercharacterized. Leveraging mLOY assessment in over 12,000 men, including 5,097 from the COPDGene Study and 7,235 from six additional cohorts in Trans-Omics for Precision Medicine program, we investigated its association with respiratory outcomes and epigenetic aging. Cross-sectionally, mLOY was associated with airflow obstruction with prevalence increasing with age, particularly in men with a former smoking history. Longitudinally, mLOY associated with lung function decline. Notably, mLOY was also associated with greater CT-quantified lung emphysema and faster pace epigenetic aging. Prospectively, in participants with normal lung function at baseline, mLOY was associated with lower future lung function and faster pace of epigenetic aging. These associations remained robust after adjusting for clonal hematopoiesis and telomere length. Collectively, these findings position mLOY as a potential biomarker of respiratory aging and obstructive lung disease. Graphical Abstract

Year:

2025

Background: Late bladder toxicity is a concern for patients receiving prostate cancer radiotherapy and negatively affects survivors. Few risk factors are known beyond the radiation dose and volume of bladder exposed. A polygenic risk score (PRS) could identify susceptible patients. Methods: A PRS was built using genome-wide association results from the Radiogenomics Consortium ( N = 3,988) and then tested in the prospective REQUITE and URWCI studies ( N = 2,034). The primary outcome was time to patient–reported gross [grade ≥2, (≥G2)] hematuria, analyzed using Cox proportional hazards regression. Secondary outcomes were ≥G2 urinary retention and frequency. The PRS was externally validated for clinically diagnosed irradiation cystitis in the UK Biobank ( N = 8,430). A gene-burden test evaluated rare coding variants. Results: A 115-variant PRS was associated with a significantly increased risk of ≥G2 hematuria [hazard ratio (HR) per SD = 1.22; P = 0.009] as well as urinary retention (HR per SD = 1.18; P = 0.016) and frequency (HR per SD = 1.14; P = 0.036). When binarized, men in the upper decile (PRS high ) had a >2-fold increased risk of hematuria after adjusting for clinical risk factors [HR = 2.12; P = 0.002; Harrel’s concordance index = 0.71 (95% confidence interval, 0.65–0.76)]. A similar effect size was seen in the UK Biobank for clinically diagnosed irradiation cystitis [odds ratio (OR) = 2.15; P = 0.026]. The burden test identified BOD1L1 as a putative novel radiosensitivity gene. Conclusions: This PRS identifies susceptible patients and could guide the selection of those needing reoptimized treatment plans that spare the bladder beyond currently recommended constraints. Impact: PRS-guided treatment planning in radiation oncology could lower the incidence of clinically relevant bladder toxicity and reduce the impact of this outcome on prostate cancer survivors.

Year:

2025

Genome-wide association studies (GWAS) have become well-powered to detect loci associated with telomere length. However, no prior work has validated genes nominated by GWAS to examine their role in telomere length regulation. We conducted a multi-ancestry meta-analysis of 211,369 individuals and identified five novel association signals. Enrichment analyses of chromatin state and cell-type heritability suggested that blood/immune cells are the most relevant cell type to examine telomere length association signals. We validated specific GWAS associations by overexpressing KBTBD6 or POP5 and demonstrated that both lengthened telomeres. CRISPR/Cas9 deletion of the predicted causal regions in K562 blood cells reduced expression of these genes, demonstrating that these loci are related to transcriptional regulation of KBTBD6 and POP5 . Our results demonstrate the utility of telomere length GWAS in the identification of telomere length regulation mechanisms and validate KBTBD6 and POP5 as genes affecting telomere length regulation.

Year:

2024

Background: Breast cancer has been associated with monogenic, polygenic, and epidemiologic (clinical, reproductive, and lifestyle) risk factors, but studies evaluating the combined effects of these factors have been limited. Methods: We extended previous work in breast cancer risk modeling, incorporating pathogenic variants (PV) in six breast cancer predisposition genes and a 105-SNP polygenic risk score (PRS), to include an epidemiologic risk score (ERS) in a sample of non-Hispanic White women drawn from prospective cohorts and population-based case–control studies, with 23,518 cases and 22,832 controls, from the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Results: The model predicts 4.4-fold higher risk of breast cancer for postmenopausal women with no predisposition PV and median PRS, but with the highest versus lowest ERS. Overall, women with CHEK2 PVs had >20% lifetime risk of breast cancer. However, 15.6% of women with CHEK2 PVs and a family history of breast cancer, and 45.1% of women with CHEK2 PVs but without a family history of breast cancer, had low ( CHEK2 PV carriers at the 10th percentile of the joint distribution of ERS and PRS, without a family history of breast cancer, had a predicted lifetime risk similar to the general population. Conclusions: These results illustrate that an ERS, alone and combined with the PRS, can contribute to clinically relevant risk stratification. Impact: Integrating monogenic, polygenic, and epidemiologic risk factors in breast cancer risk prediction models may inform personalized screening and prevention efforts.

Year:

2024

Supplementary Table S1 shows number of cases and controls and distribution by participating studies, age groups, and family history of breast cancer (first-degree relatives) in CARRIERS consortium

Year:

2024

Collaborators (79)

William A. Hall

-

UNITED STATES
View details

Tomáš Zima

Head of Institute

Charles University and General University Hospital in Prague, First Faculty of Medicine

CZECH REPUBLIC
View details

Hongying Sun

Assistant Professor

University of Rochester Medical Center

UNITED STATES
View details

Kathleen Claes

Full professor

Ghent University Hospital

BELGIUM
View details

Giuseppe Matullo

-

ITALY
View details

Lisa Wiesmüller

Professor

Ulm University

GERMANY
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Eric Hahnen

-

GERMANY
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Sara Lindström

University of Washington

UNITED STATES
View details

Maria Rossing

Associate Clinical Professor

Copenhagen University Hospital

DENMARK
View details

Marco Montagna

Istituto Oncologico Veneto

ITALY
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Nicoletta Resta

Full Professor Medical Genetics

University of Bari Aldo Moro

ITALY
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Maria Piane

Sapienza University of Rome

ITALY
View details

Laura Raffield

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Sara González

Institut Català d'Oncologia

SPAIN
View details

Jing Dong

Medical College of Wisconsin

UNITED STATES
View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES
View details

Matthew Conomos

Senior Research Scientist

University of Washington

UNITED STATES
View details

Katie O'Brien

Staff Scientist

National Institute of Environmental Health Sciences

UNITED STATES
View details

Robert Kaplan

PROFESSOR

Albert Einstein College of Medicine

UNITED STATES
View details

Rebecca Keener

Johns Hopkins University

UNITED STATES
View details

Zongli Xu

Staff Scientist

National Institute of Environmental Health Sciences

UNITED STATES
View details

April Carson

University of Mississippi Medical Center

UNITED STATES
View details

Alexandra Martins

INSERM

FRANCE
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Alexander E Volk

-

GERMANY
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Mariarosaria Calvello

European Institute of Oncology

ITALY
View details

Alison Margaret Dunning

University of Cambridge

UNITED KINGDOM
View details

anna coppa

Sapienza University of Rome

ITALY
View details

Allison DePersia

NorthShore University HealthSystem

UNITED STATES
View details

Brian Marples

Dr. Sidney H. and Barbara L. Sobel Professor in Radiation Oncology

University of Rochester Medical Center

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Florentia Fostira

National Centre for Scientific Research-Demokritos

GREECE
View details

Paolo Radice

Head of Reserach Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Maria Elena. Martinez

University of California

UNITED STATES
View details

Marketa Janatova

Assistanf Professor and researcher

Přírodovědecká Fakulta, Univerzita Karlova

CZECH REPUBLIC
View details

Carol Greider

Professor

University of California, Santa Cruz

UNITED STATES
View details

Joshua Weinstock

Assistant Professor

Emory University

UNITED STATES
View details

Gareth Evans

The University of Manchester

UNITED KINGDOM
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Weng Khong Lim

Assistant Professor

Duke-NUS Medical School

SINGAPORE
View details

Barbara Pasini

Associate Professor of Medical Genetics

Università degli Studi di Torino

ITALY
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Yasminka Jakubek

University of Kentucky

UNITED STATES
View details

Megan M Shuey

Vanderbilt University Medical Center

UNITED STATES
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES
View details

Harry Ostrer

Professor

Yeshiva University Albert Einstein College of Medicine

UNITED STATES
View details

Daniel Levy

Director/Branch Chief/Medical Officer

National Heart Lung and Blood Institute

UNITED STATES
View details

Banu K. Arun

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Helen Meier

Research Assistant Professor

University of Michigan

UNITED STATES
View details

Karen Mustian

Professor

University of Rochester Medical Center

UNITED STATES
View details

Christopher Talbot

Professor of Radiotherapy Genetics

University of Leicester

UNITED KINGDOM
View details

Michelle C. Janelsins

Division Chief and Professor

University of Rochester Medical Center

UNITED STATES
View details

Alvaro Monteiro

Senior Member - Full Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Juan Manuel Peralta

Assistant Professor of Research

The University of Texas Rio Grande Valley

UNITED STATES
View details

Corinna Ernst

Hannover Medical School

GERMANY
View details

Allison W Kurian

Professor

Stanford University School of Medicine

UNITED STATES
View details

Tiziana Rancati

Researcher

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Ananya Choudhury

The University of Manchester

UNITED KINGDOM
View details

Edward Messing

Professor

University of Rochester Medical Center

UNITED STATES
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Lidia Feliubadaló

Institut Català d'Oncologia

SPAIN
View details

Koichi Matsuda

University of Tokyo

JAPAN
View details

Catharine West

The University of Manchester

UNITED KINGDOM
View details

Joanne Ngeow

Head

Nanyang Technological University (NTU)

SINGAPORE
View details

Zdenek Kleibl

Laboratory of oncogenetics (head)

Charles University, First Faculty of Medicine

CZECH REPUBLIC
View details

Sarah Kerns

Associate Professor

Medical College of Wisconsin

UNITED STATES
View details

Nicholas Boddicker

Research Associate

Mayo Clinic

UNITED STATES
View details

Amanda Toland

Ohio State University

UNITED STATES
View details

Michael Cho

Brigham and Women's Hospital

UNITED STATES
View details

Laura Cortesi

University of Modena and Reggio Emilia

ITALY
View details